Company profile for Avobis Bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Avobis Bio is dedicated to transforming patients' lives by developing implantable biological therapies that promote tissue healing. We are pioneering the first implantable cell therapy specifically designed to heal perianal fistulas, a condition that significantly impacts quality of life. Established as a joint venture between Mayo Clinic and W. L. Gore & Associates, Inc., Avobis Bio combines clinical expertise with advanced m...
Avobis Bio is dedicated to transforming patients' lives by developing implantable biological therapies that promote tissue healing. We are pioneering the first implantable cell therapy specifically designed to heal perianal fistulas, a condition that significantly impacts quality of life. Established as a joint venture between Mayo Clinic and W. L. Gore & Associates, Inc., Avobis Bio combines clinical expertise with advanced material science to create innovative, curative therapies for patients with challenging, non-healing wounds.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
551 Paper Mill Rd. Newark, DE 19711
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/avobis-bio-presents-positive-primary-analysis-results-from-the-randomized-multicenter-stomp2-clinical-trial-at-a-plenary-session-of-the-american-college-of-gastroenterologys-annual-scientific-meeting-302598288.html

PR NEWSWIRE
29 Oct 2025

https://www.prnewswire.com/news-releases/fda-grants-rmat-designation-to-avobis-bios-implantable-cell-therapy-avb-114-for-crohns-perianal-fistulas-302574412.html

PR NEWSWIRE
03 Oct 2025

https://www.prnewswire.com/news-releases/avobis-bio-completes-primary-analysis-of-stomp-ii-randomized-clinical-trial-of-avb-114-in-crohns-perianal-fistulas-302522407.html

PR NEWSWIRE
08 Aug 2025

https://www.prnewswire.com/news-releases/avobis-bio-receives-fda-fast-track-designation-for-avb-114-implantable-cell-therapy-for-crohns-perianal-fistulas-302386006.html

PR NEWSWIRE
27 Feb 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty